Clinical Trials Browser

Phase 1/2 × Multiple Myeloma × Nivolumab × Clear all

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT02681302 2025-07-25

CPIT001

Phase 1/2 Terminated

46 enrolled 13 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT03292263 2024-05-07

ASCT With Nivolumab in Patients With Multiple Myeloma

Phase 1/2 Active not recruiting

Multiple Myeloma